Precision Biologics Announces Publication Of First-In-Human Phase 1 Clinical Trial With NEO-201
Precision Biologics, Inc. publishes data and analysis from recent First-In-Human Phase 1 Clinical Trial With...
06Apr
14Mar
Dr. Philip M. Arlen gives keynote address on NEO-201 Developments at World Antibody Congress, San Diego, CA, March 20th, 2023
Dr. Philip M. Arlen, President and CEO, Precision Biologics, gives keynote address entitled “Preclinical/Clinical Development...
14Dec
Read more...
01Dec
Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201
Precision Biologics, Inc. publishes paper on latest findings of the unique target that NEO-201 recognizes,...
09Nov
Precision Biologics To Deliver Poster Presentations On Clinical And Scientific Programs At Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
BETHESDA, Md.--(BUSINESS WIRE)--Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, will present...
09Nov
SITC 2022 – Posters will be presented in person at the Boston Convention & Exhibition Center on Thursday, November 10th, 2022
Society for the Immunotherapy of Cancer 2022 Annual Meeting, November 8 – 12, Boston, MA,...
04Oct
Dr. Philip M. Arlen gives presentation on recent NEO-201 clinical development at Biomarkers & Immuno US, 4th Annual Advances in Immuno-Oncology USA Congress, San Diego, CA, October 4, 2022
Dr. Philip M. Arlen gives presentation “Preclinical/Clinical Development of a Neo-Epitope Targeted Monoclonal Antibody for...
05Jun
Precision Biologics, Inc. and National Cancer Institute Collaborators Deliver Poster Presentation at the ASCO Annual Meeting June 5, 2022
Precision Biologics, Inc. and our collaborators at the NCI deliver a poster presentation at the...
07Apr
Dr. Philip M. Arlen provides perspective on the role of biomarkers for cancer immunotherapy at Oxford Global’s 2021 Biomarkers UK Conference
Dr. Philip M. Arlen provides perspective on the role of biomarkers for cancer immunotherapy at...
22Mar
Precision Biologics, Inc. Announces Issuance of U.S. Patent: “MONOCLONAL ANTIBODY NEO-201 FOR THE TREATMENT OF HUMAN CARCINOMAS”
Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announces that the U.S....